Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Imprimis Phar (IMMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 132,463
  • Shares Outstanding, K 23,280
  • Annual Sales, $ 26,770 K
  • Annual Income, $ -11,990 K
  • 60-Month Beta -1.00
  • Price/Sales 4.51
  • Price/Cash Flow N/A
  • Price/Book 26.92
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.30
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/13/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.84
  • Number of Estimates 1
  • High Estimate 0.84
  • Low Estimate 0.84
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +746.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.44 +28.15%
on 12/03/18
6.50 -12.46%
on 12/11/18
+0.96 (+20.30%)
since 11/30/18
3-Month
2.22 +156.31%
on 10/11/18
6.50 -12.46%
on 12/11/18
+2.91 (+104.68%)
since 09/28/18
52-Week
1.45 +292.41%
on 01/26/18
6.50 -12.46%
on 12/11/18
+3.99 (+234.71%)
since 12/29/17

Most Recent Stories

More News
Harrow Health Announces Fourth Quarter 2018 Financial Results

Harrow Health, Inc. (NASDAQ: HROW) today reported results for the fourth quarter 2018.

IMMY : 5.69 (+9.63%)
HROW : 5.31 (-2.57%)
Harrow Health to Attend 31st Annual ROTH Conference on March 18, 2019

Harrow Health, Inc. (NASDAQ: HROW) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019 at The Ritz Carlton, Laguna Niguel in Dana Point, CA. Mark L. Baum, the company's...

IMMY : 5.69 (+9.63%)
HROW : 5.31 (-2.57%)
Harrow Health to Announce Fourth Quarter 2018 Financial Results on March 12, 2019

Harrow Health, Inc. (NASDAQ: HROW) today announced it will release fourth quarter 2018 financial results after the close of trading on Tuesday, March 12, 2019. The company will host a conference call...

IMMY : 5.69 (+9.63%)
HROW : 5.31 (-2.57%)
Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulations

Melt Pharmaceuticals, Inc., a specialty pharmaceutical company recently deconsolidated from Harrow Health, Inc. (NASDAQ: HROW), today announced the U.S. Patent and Trademark office has issued two additional...

IMMY : 5.69 (+9.63%)
HROW : 5.31 (-2.57%)
Harrow Health Subsidiary, Mayfield Pharmaceuticals, Inc., Acquires Patented Dyspareunia Drug Candidate and Other Intellectual Property

Harrow Health, Inc. (NASDAQ: HROW), today announced that its subsidiary, Mayfield Pharmaceuticals, Inc., has acquired drug formulation assets and intellectual property, including three recently issued...

IMMY : 5.69 (+9.63%)
HROW : 5.31 (-2.57%)
Harrow Health Announces $11 Million Series A Financing for Melt Pharmaceuticals Subsidiary

Melt Pharmaceuticals, Inc., an affiliated company of Harrow Health, Inc. (NASDAQ: HROW), today announced it has entered into definitive stock purchase agreements with accredited and institutional investors...

IMMY : 5.69 (+9.63%)
KERX : 3.36 (-2.04%)
HROW : 5.31 (-2.57%)
AMAG : 12.16 (-4.33%)
Best Sector of 2018 and its Hit ETFs & Stocks

Healthcare was the best-performing sector of 2018 and we have highlighted top-performing ETFs and stocks from this sector.

HEMA : 13.7500 (-5.50%)
IMMY : 5.69 (+9.63%)
XLV : 90.62 (-1.82%)
VHT : 170.46 (-2.07%)
XHE : 79.78 (-3.25%)
TNDM : 68.76 (-6.53%)
PRQR : 15.00 (-0.20%)
IHI : 227.71 (-2.48%)
CDNA : 36.92 (-5.84%)
PSCH : 114.49 (-4.01%)
Best Sector of 2018 and its Hit ETFs & Stocks

Healthcare was the best-performing sector of 2018 and we have highlighted top-performing ETFs and stocks from this sector.

HEMA : 13.7500 (-5.50%)
IMMY : 5.69 (+9.63%)
XLV : 90.62 (-1.82%)
VHT : 170.46 (-2.07%)
XHE : 79.78 (-3.25%)
TNDM : 68.76 (-6.53%)
PRQR : 15.00 (-0.20%)
IHI : 227.71 (-2.48%)
CDNA : 36.92 (-5.84%)
PSCH : 114.49 (-4.01%)
Imprimis Pharmaceuticals, Inc. Completes Name Change to Harrow Health, Inc.

Harrow Health, Inc. (formerly known as Imprimis Pharmaceuticals, Inc.) (NASDAQ: IMMY) announced it has formally changed its name and that it will trade as "HROW" on The NASDAQ Capital Markets beginning...

IMMY : 5.69 (+9.63%)
HROW : 5.31 (-2.57%)
Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Abeona Therapeutics Inc. (NASDAQ:ABEO),...

IMMY : 5.69 (+9.63%)
CYTK : 8.75 (-1.02%)
AUPH : 6.47 (-4.15%)
LNT : 47.55 (+0.91%)
GLDD : 9.08 (+0.89%)
ABEO : 7.52 (-9.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade IMMY with:

Business Summary

Imprimis Pharmaceuticals, Inc. is a pharmaceutical company focused on its proprietary ophthalmology and urology drug formulations. Imprimis recently launched its urology business, which includes a patented formulation to address patients suffering from interstitial cystitis.

See More

Key Turning Points

2nd Resistance Point 6.17
1st Resistance Point 5.93
Last Price 5.69
1st Support Level 5.35
2nd Support Level 5.01

See More

52-Week High 6.50
Last Price 5.69
Fibonacci 61.8% 4.57
Fibonacci 50% 3.97
Fibonacci 38.2% 3.38
52-Week Low 1.45

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar